IsoPlexis’ Expanded Cell Therapy Offerings Demonstrated in Nature Medicine Publications


Company broadens vary of workflows in “Functional Cell Library” to speed up cell remedy manufacturing and scientific research

BRANFORD, Conn., Nov. 18, 2021 /PRNewswire/ — IsoPlexis Corporation (NASDAQ: ISO), the chief in purposeful single-cell proteomics, in the present day introduced the publication of two high-impact scientific analysis research in Nature Medicine. Both papers exhibit the distinctive utility of IsoPlexis’ single-cell proteomic platform for predicting the efficiency of novel cell therapies, together with chimeric antigen receptor (CAR) T cells in blood most cancers and tumor infiltrating lymphocytes (TILs) in opposition to stable tumors.


In addition, IsoPlexis has broadened its “purposeful cell library” of obtainable workflows to cowl vastly extra engineered cell varieties to fulfill wants in the quickly increasing cell remedy house. Other than autologous and allogeneic CAR-T cells and TILs, these embrace pure killer (NK) cells, T-cell receptor transgenic T cells (TCR-T), and numerous forms of monocytes. The continued growth of this library of proteomically-driven single cells supplies the flexibility to characterize a complete vary of cell remedy product varieties to propel the fast-moving cell remedy trade.

“One of the best challenges in enhancing cell therapies is knowing precisely how these residing immune medicine work, as early as doable. Through these two high-impact publications, the researchers leveraged our distinctive single-cell proteomic evaluation to achieve a greater understanding of how CAR-Ts and TILs perform, which then led to improved assessments of high quality, efficiency, and sturdiness,” mentioned Sean Mackay, CEO and co-founder of IsoPlexis.

Data from the corporate’s single-cell purposeful proteomics platform was printed in Nature Medicine by researchers from Stanford University. The paper, titled “CAR T cells with twin focusing on of CD19 and CD22 in grownup sufferers with recurrent or refractory B cell malignancies: a section 1 trial,” identifies early indicators of response or relapse in CAR-T remedy, leveraging IsoPlexis’ platform. The researchers discovered that purposeful protein manufacturing from single cells is a significant attribute to foretell the efficiency of CAR-T cell therapies. “Our outcomes counsel that engineering iterations ought to be guided by cautious research of single-cell CAR polyfunctionality incorporating cytokine manufacturing as a crucial high quality attribute.”

In one other Nature Medicine paper titled “Tumor-infiltrating lymphocyte therapy for anti-PD-1-resistant metastatic lung most cancers: a section 1 trial”, researchers from Duke University and Moffit Cancer Center printed information on therapy response and efficiency in TIL remedy utilizing IsoPlexis’ single-cell purposeful proteomics platform. The platform’s purposeful readouts had been proven to be crucial for understanding affected person response to the novel TIL therapies. “We assessed the polyfunctional energy index (PSI), which is an indicator of the variety of cells able to secreting a number of forms of cytokines. As PSI displays the flexibility of a T cell to hold out a number of capabilities, it’s acknowledged as a metric for the efficiency of cell remedy and for the efficacy of vaccines.”

Visit our publications web page to see the big selection of use instances for single-cell proteomics in accelerating a wide range of cell therapies in excessive influence publications.

About IsoPlexis

IsoPlexis is main a brand new period of purposeful proteomics. By figuring out our most proteomically energetic single cells (or “superhero cells”) for the primary time, IsoPlexis allows researchers to attach extra on to in vivo biology and develop extra exact and customized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and a number of others. The IsoPlexis platform is used globally by researchers, together with these on the high 15 world pharmaceutical firms and on the majority of main U.S. complete most cancers facilities.

Cautionary Note Regarding Forward Looking Statements

Certain statements in this press launch are forward-looking statements which are topic to dangers and uncertainties that might trigger outcomes to be materially completely different than expectations. Important elements that might trigger precise outcomes to vary materially embrace: the speed of adoption of the Company’s know-how by its prospects and potential prospects in addition to the chance elements set forth in the Risk Factors part of the Company’s prospectus filed with the SEC. These forward-looking statements usually are not ensures of future efficiency and converse solely as of the date hereof, and, besides as required by regulation, IsoPlexis disclaims any obligation to replace these forward-looking statements to mirror future occasions or circumstances.

Investor Contact

Press Contact

Related Links



View authentic content material to obtain multimedia:

SOURCE IsoPlexis